investing.comNov 5$NTLA

Intellia Therapeutics Inc earnings missed by $0.11, revenue fell short of estimates

Intellia Therapeutics (NTLA) reported Q3 EPS of -$0.91, missing estimates by $0.11, and revenue of $7.16M, below the $10.23M consensus. The stock is up 3.1% over 3 months but down 0.08% year-over-year. Analysts have mixed EPS revisions, and InvestingPro rates its financial health as 'fair performance.'

Original reporting

investing.com

Published Nov 5, 2026, 1:25 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 1:41 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$NTLA

Bearish

medium confidence

Mentioned

$NTLA

Relevance

6/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$NTLABearishMed

Why it matters

The earnings miss could trigger a short‑term decline in NTLA shares, while longer‑term valuation will depend on pipeline milestones.

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders focused on biotech earnings momentum.

What to watch

Potential upcoming regulatory approvals or partnership announcements could offset the short‑term disappointment.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Intellia Therapeutics (NASDAQ: NTLA) is a CRISPR gene‑editing company. The article provides its latest quarterly financial results.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NTLABearishMedium confidence

Context

Intellia Therapeutics reported Q3 EPS of -$0.91 and revenue of $7.16M, both missing analyst estimates.

Expected impact

downward pressure as investors price in the revenue and EPS shortfall

Evidence & confidence

The miss on both earnings and revenue is material for a biotech micro‑cap, suggesting short‑term downside.

Market effects

Sector

May weigh on other gene‑editing biotech stocks as investors reassess sector expectations.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Low global impact; primarily relevant to US‑listed biotech investors.

Counterpoint

What could challenge this read

Some investors may view the miss as a buying opportunity if they believe the pipeline remains strong.

Key entities

company
Intellia Therapeutics Inc
CRISPR gene‑editing biotech reporting Q3 results.

Read at source ← All news

$NTLAMed

Intellia Therapeutics Announces Third Quarter 2026 Financial Results

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ

SEC EDGAR 8-KNov 5

$NTLALowAI 8/10

Intellia concludes Phase III ATTRv-PN study enrolment

Intellia Therapeutics completed patient enrolment in the Phase III MAGNITUDE-2 study for nexiguran ziclumeran (nex-z), a CRISPR-based treatment for ATTRv-PN. The trial will assess safety and efficacy in 60 adults, with primary outcomes measured at day 29 and month 18. Intellia aims to halt or reverse disease progression with a single dose. The therapy is also being studied for ATTR-CM and has received regulatory designations from the FDA and European Commission.

clinicaltrialsarena.comNov 5

$NTLAMedAI 8/10

Intellia completes enrollment in phase 3 trial for ATTRv-PN therapy

Intellia Therapeutics (NASDAQ:NTLA) completed enrollment in the MAGNITUDE-2 phase 3 trial for nex-z, a CRISPR-based therapy for ATTRv-PN. The trial involves 60 patients and evaluates efficacy and safety over 18 months. Nex-z is also being tested in a separate phase 3 trial for ATTR-CM and has received Orphan Drug and RMAT designations. Intellia collaborates with Regeneron on its development.

investing.comNov 4

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

genengnews.comNov 1

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.comOct 28

$NTLALow

Jing Marantz helped advance several approved rare-disease therapies. On Oct. 26, she becomes Intellia’s medical chief.

Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.

stocktitan.netOct 13